TP63 and adrenal cortex carcinoma: Of note, functional analysis of samples clustered based on p63 immunostaining revealed highly consistent pathway alterations in p63-negative tumors and in early relapsing patients, suggesting a link between molecular events underlying the pathway p63 negative (mostly solid tumor and with high Ki67) and ACC adverse outcome.